tailieunhanh - Báo cáo y học: "HIV-1 Capsid Assembly Inhibitor (CAI) Peptide: Structural Preferences and Delivery into Human Embryonic Lung Cells and Lymphocyte"

Tuyển tập các báo cáo nghiên cứu khoa học ngành y học tạp chí Medical Sciences dành cho các bạn sinh viên ngành y tham khảo đề tài: HIV-1 Capsid Assembly Inhibitor (CAI) Peptide: Structural Preferences and Delivery into Human Embryonic Lung Cells and Lymphocytes. | Int. J. Med. Sci. 2008 5 230 International Journal of Medical Sciences ISSN 1449-1907 2008 5 5 230-239 Ivyspring International Publisher. All rights reserved Research Paper HIV-1 Capsid Assembly Inhibitor CAI Peptide Structural Preferences and Delivery into Human Embryonic Lung Cells and Lymphocytes Klaus Braun1 Martin Frank2 Rudiger Pipkorn3 Jennifer Reed4 Herbert Spring5 Jurgen Debus6 Bernd Didinger6 Claus-Wilhelm von der Lieth2 Manfred Wiessler1 Waldemar Waldeck7 1. German Cancer Research Center Division of Molecular Toxicology INF 280 D-69120 Heidelberg Germany 2. German Cancer Research Center Division Central Spectroscopy B090 INF 280 D-69120 Heidelberg Germany 3. German Cancer Research Center Core Facility Peptide Synthesis INF 580 D-69120 Heidelberg Germany 4. German Cancer Research Center Biomolecular Mechanisms INF 280 D-69120 Heidelberg Germany 5. German Cancer Research Center Research Group Structural Biochemistry INF 280 D-69120 Heidelberg Germany 6. University of Heidelberg Radiation Oncology INF 110 D-69120 Heidelberg 7. German Cancer Research Center Division of Biophysics of Macromolecules INF 580 D-69120 Heidelberg Germany Correspondence to Dr. Klaus Braun German Cancer Research Center DKFZ Dept. of Molecular Toxicology Im Neuenheimer Feld 280 D-69120 Heidelberg Germany. Phone 49 6221-42 2495 Fax 49 6221-42 2442 e-mail Received Accepted Published The Human immunodeficiency virus 1 derived capsid assembly inhibitor peptide HIV-1 CAI-peptide is a promising lead candidate for anti-HIV drug development. Its drawback however is that it cannot permeate cells directly. Here we report the transport of the pharmacologically active CAI-peptide into human lymphocytes and Human Embryonic Lung cells HEL using the BioShuttle platform. Generally the transfer of pharmacologically active substances across membranes demonstrated by confocal laser scanning microscopy CLSM could lead to a loss of function